Investing in biotech stocks isn't for everyone. An unsuccessful clinical trial can cause a huge decline. The competition is ...

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined around 1.2% in the past three months, losing almost $3 ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

Vertex Energy (VTNR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Vertex ...

Vertex stock advanced Tuesday as analysts debated the company's pain drug, VX-548, with one saying it could eventually be ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

This was the stock's second consecutive day of losses.

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined around 1.2% in the past three months, losing almost $3 billion of its market value. A key reason for the stock price dip was the ...